Success Metrics

Active Trials
1(20%)

Phase Distribution

Ph phase_2
2
40%
Ph phase_4
1
20%
Ph not_applicable
2
40%

Phase Distribution

0

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
2(40.0%)
Phase 4Post-market surveillance
1(20.0%)
N/ANon-phased studies
2(40.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

5

all time

Status Distribution
Active(5)

Detailed Status

Not yet recruiting4
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
1
Success Rate
N/A
Most Advanced
Phase 4

Trials by Phase

Phase 22 (40.0%)
Phase 41 (20.0%)
N/A2 (40.0%)

Trials by Status

not_yet_recruiting480%
recruiting120%

Recent Activity

1 active trials
Showing 5 of 5
not_yet_recruitingnot_applicable

INtensive liPid-lowering Therapy for Acute High-risk IntracRanial or Extracranial atheroSclerosis -II (INSPIRES-2)

NCT07341958
not_yet_recruitingphase_4

Effectiveness of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Initiation Before Percutaneous Coronary Intervention on Acute Myocardial Infarction Patients

NCT06683131
not_yet_recruitingphase_2

Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

NCT07061535
recruitingphase_2

A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.

NCT06421298
not_yet_recruitingnot_applicable

Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese Population

NCT06096909

Clinical Trials (5)

Showing 5 of 5 trials
NCT07341958Not Applicable

INtensive liPid-lowering Therapy for Acute High-risk IntracRanial or Extracranial atheroSclerosis -II (INSPIRES-2)

Not Yet Recruiting
NCT06683131Phase 4

Effectiveness of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Initiation Before Percutaneous Coronary Intervention on Acute Myocardial Infarction Patients

Not Yet Recruiting
NCT07061535Phase 2

Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

Not Yet Recruiting
NCT06421298Phase 2

A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.

Recruiting
NCT06096909Not Applicable

Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese Population

Not Yet Recruiting

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5